Vivus' announcement that the company is looking to partner with Big Pharma for marketing help to get its new weight-loss drug, Qsymia, off the ground apparently encouraged investors. Shares rose 9.7% to $13.21, the biggest one-day increase since Dec. 17, Bloomberg reported.
The DEA has made its decision on Belviq, the weight-loss drug that's been sitting on Arena's launching pad since its FDA approval last June. Belviq is now officially a Schedule IV controlled substance, and Arena can fire up its engines for a launch next month.
Arena Pharmaceuticals has decided to take its drug application and go home. The drugmaker Friday said it was giving up for now on breaking through the European wall of resistance to its weight-loss drug Belviq. The company, which got FDA approval last year, yanked its application with little explanation.
Arena Pharmaceuticals pulled the plug on its application for approval of the obesity drug Belviq with European regulators, another blow to the commercial and regulatory effort behind the treatment. The San Diego-based biotech revealed the decision to withdraw the app in its first-quarter financial report late Thursday afternoon.
Just in time for New Year's resolutions, The Financial Times rounds up the latest on a new generation of obesity drugs.
Could Eisai have an obesity drug just waiting to step onstage? The Japanese drugmaker's epilepsy treatment Zonegran helped patients lose weight--at least as much weight as patients in Arena Pharmaceuticals' ($ARNA) trial of its recently approved Belviq.
Good news for Vivus: Many payers don't mind footing the bill for its weight-loss drug Qsymia. During the product's first week on the market, insurers agreed to pay for about one-third of prescriptions. That could help the drug gain traction before its rival, Arena Pharmaceuticals' Belviq, clears the Drug Enforcement Administration.
Vivus has won an early weight-loss race in the marketplace. The company launched its Qsymia treatment, beating competitor Arena Pharmaceuticals' Belviq by several months. But will it come out on top in the most important one--the contest for prescriptions and sales?
Vivus ($VVUS) has won an early weight-loss race in the marketplace. The company launched its Qsymia treatment, beating competitor Arena Pharmaceuticals' ($ARNA) Belviq by several months. But will it come out on top in the most important one--the contest for prescriptions and sales?
Eisai's chief executive has mapped out a three-prong strategy for marketing the new diet drug Belviq in early 2013. Haruo Naito says Eisai will work on patient education, enhancing disease awareness and collaborations with patient groups as it starts to campaign for insurance coverage.